MARIETTA, Ga., Nov. 7, 2014 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spinal, Sports Medicine, Ophthalmic and Dental sectors of healthcare, announced today that Christopher M. Cashman has joined MiMedx as the Company's Executive Vice President & Chief Commercialization Officer. In his new role, Mr. Cashman will contribute his expertise to the Company's sales & marketing functions, strategic planning and all related revenue growth initiatives. "We are very...
↧
